The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
What implications might the PERSIST-2 landmark OS analysis data have on the use of pacritinib in MF?
Featured:
Helen AjufoDuring the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the MPN Hub was pleased to speak to Helen Ajufo, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What implications might the PERSIST-2 landmark overall survival (OS) analysis data have on the use of pacritinib in myelofibrosis?
What implications might the PERSIST-2 landmark OS analysis data have on the use of pacritinib in MF?
In this interview, Ajufo shares insights on the latest analysis from the PERSIST-2 trial on spleen reduction as a predictor of OS in pacritinib-treated myelofibrosis. Ajufo discusses the OS data, stratified by patient platelet count and spleen volume reduction achieved, making comparisons with corresponding data from the control arm of best available therapy. This interview concludes with a look at the future application of pacritinib in myelofibrosis.
For more information on pacritinib and the PERSIST-2 trail, visit our previous coverage from ASCO and EBMT.